TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06641687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24% Sucrose
Description: Participants will be given either sugar water (24% sucrose) randomly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Participants will be given sterile water randomly
Study: NCT06650280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Description: hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nano-hydroxyapatite
Description: nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sandblasted acid etched
Description: SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
Study: NCT06650813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drépa-FACETS Program
Description: Drépa-FACETS Program for Sickle Cell Disease
Study: NCT06650254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory
Description: Stage 1: The Postpartum Breastfeeding Comfort Scale will be applied to mothers before they are admitted to the support program. On the 0th day postpartum, the researcher will go to the mother, baby and father and provide mother-baby skin-to-skin contact and breastfeeding support (Module 1).~Stage 2: The videos aimed at increasing breastfeeding comfort, which were shot for Modules 2, 3, 4 and 5 and transferred to the website, will be watched by mothers and fathers/relatives after discharge. At the same time, online counseling will be provided through the website and support will be provided for applications that will increase breastfeeding comfort.~Stage 3: Mothers who have participated in at least 70% of the breastfeeding support structured according to Kolcaba's Comfort Theory will be called after 6-8 weeks and the Postpartum Breastfeeding Comfort Scale will be applied again and their final tests will be performed.
Study: NCT05358795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections
Description: Family Connections is based on the WHO endorsed Positive Connections manual.
Study: NCT06019611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous epidural stimulation
Description: Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System
Study: NCT04873830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: volume stable collagen matrix placement
Description: volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue grafting
Description: connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
Study: NCT04896697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilastobart (XTX101)
Description: vilastobart (XTX101) monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilastobart (XTX101)
Description: vilastobart (XTX101) monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered every 3 weeks in combination with vilastobart (XTX101)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered every 3 weeks in combination with vilastobart (XTX101)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilastobart (XTX101)
Description: In combination with Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilastobart (XTX101)
Description: In combination with Atezolizumab
Study: NCT05492877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiperstat (AZD4831)
Description: Oral dosage, once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dosage, once daily.
Study: NCT06649682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NYM096 PET/CT and 177Lu-NYM096
Description: Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.
Study: NCT06650943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Consultation in Weight Management and Metabolic syndrome
Description: Based on the Carbohydrate-insulin Theory
Study: NCT06653738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Once daily per os for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Once daily per os for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily per os for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily per os for 3 years

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized dietary counseling
Description: Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Personalized dietary counseling
Description: Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic dietary counseling
Description: Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic dietary counseling
Description: Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
Study: NCT06651814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Group
Description: A supervised exercise program will consists of 10 sessions. The 1st exercise station will be a 5-minute warming up of the jaw with a heat lamp. The 2nd station will involve jaw opening-closing movements (TMJ rotation) with the mandible in a slightly protruded position for 6 minutes. The 3rd and 4th exercise stations will comprised of jaw opening and jaw protrusion, respectively, against resistance for 4 minutes each. Measurements will be done before the trial started and after 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Group
Description: Patients will received a home regime of jaw exercises. They will be instructed to do two different trainings. The 1st type of exercise will be jaw opening and closing movements daily for 5 minutes after each meal with the mandible and the head of the TMJ in a slightly protruded position. This exercise should not produce any clicking sounds. The 2nd type of exercise will be isometric exercises; this entailed jaw opening and jaw protrusion against resistance with their hand for 10 seconds with 10 repetitions each daily. All the patients will receive a training brochure with photos of the exercises and detailed information on frequency and exercise time. The brochure will include a diary. After 6 weeks, the subject and the assistant will check the performance of the exercise and the diary
Study: NCT06653868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant with bone augmentation
Description: gap distance augmentation with bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant with bone augmentation
Description: gap distance augmentation with bone graft
Study: NCT06653673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChatGPT supported Online Guided Self-Help Program (GSHP)
Description: Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily
Study: NCT06652087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard HFpEF treatment
Description: diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard HFpEF treatment
Description: diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
Study: NCT06338176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIMUS-SAB clinical care pathway
Description: Activation of SAB clinical care pathway within EMR system.
Study: NCT05409157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Specified dose on specified days
Study: NCT05834140

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~* MET of the scaleni~* MET of Sternocleidomastoid~* MET of Levator Scapulae~* MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days
Study: NCT05802147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact
Description: skin-to-skin contact
Study: NCT05972434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen A
Description: Participants will apply sunscreen A topically.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen B
Description: Participants will apply sunscreen B topically.
Study: NCT06572657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive stimulation
Description: cognitive stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: physical exercise
Study: NCT05494125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
Study: NCT04655404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: 1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone
Study: NCT06291597

Intervention type: OTHER
Intervention: Vaping
Description: Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
Study: NCT04655404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: 1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Larotrectinib surgical
Description: 1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone
Study: NCT06573840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroGlove
Description: NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroGlove
Description: NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
Study: NCT06538961

Intervention type: OTHER
Intervention: Collection of blood samples
Description: the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from individuals where the amount of blood does not exceed allowable amounts (see help).

Intervention type: OTHER
Intervention: Collection of blood samples
Description: the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from individuals where the amount of blood does not exceed allowable amounts (see help).
Study: NCT06100068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Exercises and Temporal Alteration
Description: Mental exercises during L-DIBH to distort the awareness of passage of time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Exercises and Temporal Alteration
Description: Mental exercises during L-DIBH to distort the awareness of passage of time
Study: NCT04805983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-984923
Description: Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-984923
Description: Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-984923
Description: Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
Study: NCT06538961

Intervention type: OTHER
Intervention: Data Collection
Description: Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.

Intervention type: OTHER
Intervention: Data Collection
Description: Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.

Intervention type: OTHER
Intervention: Urine Sample
Description: Post-transplant monthly urine sample collection for 6 months

Intervention type: OTHER
Intervention: Urine Sample
Description: Post-transplant monthly urine sample collection for 6 months
Study: NCT06652841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transShield Embolic Protection System
Description: Patient undergoing TAVR procedure will receive the transShield EPS with the intent to capture and remove debris dislodged during the interventional procedure.
Study: NCT06652165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib combined with BEAM
Description: zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAM
Description: camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
Study: NCT06652217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digitally manufactured occlusal splint.
Description: digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventionally manufactured occlusal splint
Description: the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
Study: NCT04385719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
Study: NCT03548870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CWRT with low frequency transcutaneous electrical nerve stimulation
Description: 4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CWRT with sham-low frequency transcutaneous electrical nerve stimulation
Description: 4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
Study: NCT05691140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
Study: NCT05631639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillSense System
Description: The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
Study: NCT05075876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)
Description: Single application for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)
Description: Single application for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)
Description: Single application for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)
Description: Single application for 6 days
Study: NCT05232448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
Study: NCT05829603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamin (DMT) & Harmine
Description: Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamin (DMT) & Harmine
Description: Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
Study: NCT03709550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study: NCT05552313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: kinesio tape
Description: kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard therapy
Description: Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
Study: NCT06537583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym Neuromodulation Device (Treatment Group)
Description: Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Parasym Neuromodulation Device (Treatment Group)
Description: Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym Neuromodulation Device (Sham Group)
Description: Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Parasym Neuromodulation Device (Sham Group)
Description: Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
Study: NCT06660407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Given immunotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spatially-fractionated Radiation Therapy
Description: Undergo grid radiation therapy